PUMA BIOTECHNOLOGY, INC. Deferred Income Tax Expense (Benefit)
PUMA BIOTECHNOLOGY, INC. (PBYI) reported Deferred Income Tax Expense (Benefit) of $3.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-26
- PUMA BIOTECHNOLOGY, INC. deferred income tax expense (benefit) for fiscal 2025 was $3.25M.
- PUMA BIOTECHNOLOGY, INC. deferred income tax expense (benefit) for fiscal 2024 was -$7.08M.
- PUMA BIOTECHNOLOGY, INC. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- PUMA BIOTECHNOLOGY, INC. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $3.25M 10-K · filed 2026-02-26 |
| 2024-12-31 | -$7.08M 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |